Celcuity Inc. (CELC) Stock Price & Analysis

Celcuity Inc. (CELC) rose 0.00% to USD 82.62 as of July 25, 2026 at 04:28 UTC, according to Nexqual real-time market data.

CELC last closed at USD 82.62; the session ranged USD 82.24–89.56 on volume of 1,277,422 shares. Market capitalization is —, with a 52-week range of USD 13.59–151.02 (NCM). Source: Nexqual, July 25, 2026 at 04:28 UTC.

Key Statistics (as of July 25, 2026 at 04:28 UTC)

Technical Analysis (CELC)

Nexqual's technical model rates CELC "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:28 UTC.

From Celcuity Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)

Key Strengths & Strategy (as disclosed to the SEC)

• It is expected that approximately 200 clinical sites across North America, Europe, and Asia-Pacific will participate, including many sites included in the VIKTORIA-1 clinical trial.   In August 2025, the FDA granted our request to submit our NDA for gedatolisib under the FDA's Real-Time Oncology Review ("RTOR") program based on data from the PIK3CA WT cohort of the Phase 3 VIKTORIA-1 clinical trial.
• We are also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, including a $5.0 million milestone payment we made in January 2026 following FDA acceptance of our NDA submission, up to an aggregate of $335.0 million.
• Many of the companies against which we may compete have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products.   There are several PI3K, AKT, and mTOR inhibitors approved by the FDA, including PIQRAY and AFINITOR from Novartis AG, TRUQAP from AstraZeneca plc, ITOVEBI from F.
• We plan to protect our proprietary positions using a variety of methods, which include obtaining U.S. and foreign patents related to our inventions and improvements, and prosecuting additional U.S. and foreign patents that we determine are important to the development and implementation of our business.

Partnerships

• We also rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.       Gedatolisib Patents   We entered into the Gedatolisib License Agreement with Pfizer in April 2021, pursuant to which we acquired exclusive worldwide rights under Pfizer patents and know-how to develop, manufacture and commercialize gedatolisib.
• We may also elect to enter into agreements with other CMOs to formulate and manufacture supplies of drug substance and finished drug product.        Sales and Marketing   If any of our product candidates are approved, we intend to market and commercialize them in the U.S. and select international markets, either alone or in partnership with others.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:28 UTC. This page is informational and not investment advice.